AOCC                                                 thymoma(136)
 _________________________________________________________________
  adriamycin...... 40 mg/sqm IV day 1.
  vincristine..... 0.6 mg/sqm IV day 3.
  cytoxan......... 700 mg/sqm IV day 4.
  cisplatin....... 50 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 3 weeks, if WBC counts 
                   permit.

  reference...
    Fornasiero A.  Daniele O.  Sperandio P.  Morandi P.  Fosser 
    VP.  Cartei G.  Fiorentino MV. Chemotherapy of invasive or 
    metastatic thymoma: report of 11 cases. Cancer Treatment 
    Reports.  68(10):1205-10, 1984 Oct. 
  abstract...
    Eleven patients with invasive thymoma (seven males and four 
    females) were seen from 1977 to 1983. All patients were adults 
    with a median age of 46 years (range, 24-62), and presented 
    after surgical exploration with nonremovable primary and with 
    one or more of the following patterns of tumor extension: 
    supraclavicular lymphadenopathy (four patients), superior vena 
    cava syndrome (two), pleural effusion (nine), and pericardial 
    effusion (three). The following distant metastases were also 
    observed: lung (six patients), liver (one), skin (two), 
    peritoneum (two), bone (one), and brain (one). The 
    chemotherapy was administered in 4-day courses. All patients 
    received the following: 50 mg/m2 of cisplatin iv and 40 mg/m2 
    of doxorubicin iv on Day 1, 0.6 mg/m2 of vincristine iv on Day 
    3, and 700 mg/m2 of cyclophosphamide iv on Day 4. The course 
    was repeated every 3 weeks. Toxic effects were tolerable, as 
    expected for the drug combination adopted. Four of 11 patients 
    achieved objective complete regression of disease and six of 
    11 had partial remission, for an overall response rate of 91%; 
    one patient had stable disease for 7 months. Six patients have 
    died and the median survival has been 12.5 months, ranging 
    from 5 to 23 months.